PBMA H V Desai
Completed Clinical Trial

Institutional Ethics Committee of PBMA’s H. V. Desai Eye Hospital has been registered with DCGI under rule 122DD of the Central Drug Standard Control Organization (CDSCO)
Re-Registration Number –ECR/234/Inst/MH/2013/RR-16 which is valid for 3 years (Till 21 April 2019).

Sponsor - Lux bioscience

Protocol Title:- 1. LX201-01.- A multi center, placebo –controlled, randomized, Parallel-group, Dose Ranging study to access the efficacy and safety of LX201 for prevention of corneal Allograft Rejection episodes and graft failure following penetrating ketatoplasty with LX 201 implantation in subjects who are at increased immunological Risk.
2. LX 201-02- A multi center, placebo –controlled, randomized, Parallel-group, Dose Ranging study to access the efficacy and safety of LX201 for the prevention of corneal allograft rejection episodes Or Graft failure in subjects who experienced one or more rejection episodes following penetrating keraoplasty.

Sponsor - Sun Pharma Advance Research Company

Protocol Title:- Comparison of the efficacy and safety of Latanoprost 0.005% (Xalatan ® Reference) and Latanoprost 0.005% administered once daily in open angle glaucoma and ocular hypertension.

Sponsor - Sun Pharma Advance Research Company

Protocol Title:- Study to evaluate Safety of Benzalkonium Chloride Free Latanoprost Ophthalmic Solution 0.005% in Subjects with Glaucoma.

Sponsor – Allergan Health Care India Pvt Ltd.

Protocol Title:- A multicenter, open –label study to evaluate the safety and efficacy of twice-daily 0.0.1% Bimatoprost/ 0.15% Brimonidine /0.5% Timolol Ophthalmic Solution(Triple combination) in patient in India , who have glaucoma or ocular hypertension with elevated IOP, and are on twice –daily 0.2% Brimonidine /0.5% Timolol Ophthalmic solution(Dual Combination Therapy).

Sponsor - Sun Pharma Advance Research Company

Protocol Title:- Efficacy and safety of fixed dose combination of latanoprost 0.005% and timolol 0.5% ophthalmic solution (sun pharma advanced research company Ltd) in patients with open angle glaucoma or ocular hypertension: a randomized, evaluator masked, parallel Group, active controlled study.

Sponsor - Foresight Biotherapeutics, Inc. New York.

Protocol Title:- A proof-of-concept, multi-center, randomized, double-masked study to evaluate the Clinical efficacy and safety of FST-100 (0.1% Dexamethasone and 0.6 % PVP-Iodine ) Ophthalmic suspension in the treatment of Acute Adenoviral conjunctivitis.

Sponsor – Intas Biopharmaceutical Ltd. Ahmedabad.

Protocol Title:- A Prospective, Comparative, Assessor Blind, Randomized, Multicenteric Phase III study to compare the safety and efficacy of Ranibizumab of Intas Biopharmaceuticals Ltd. in comparison with Lucentis of Novartis in patients of wet AMD (Age related Macular Degeneration).

Sponsor - Sun Pharma Advance Research Company, Mumbai.

Protocol Title:- “Aqueous Humor Bioequivalence Study of Loteprednol 0.5 %, Sun Pharmaceutical Industries Ltd (SPIL) and Lotemax in Patients Undergoing Cataract Surgery: A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Cross over, Active Controlled Study”.

Sponsor - pSivida Corp – USA

Protocol No:- PSV-FAI-001
Protocol Title:- A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects with Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye.

Address

PBMA's H. V. Desai Eye Hospital, 93, Tarwade Vasti, Mohammadwadi road, Hadapsar, Pune MH 411060 India

Contact No

+91-20-26970144 | 26970043

+91-20-30114000 | 30114201

Working Hours

Mon to Fri - 8:00 am to 4:00 pm
Mon to Fri - 5:00 pm to 7:00 pm
Saturday : 8:00 am to 2:00 pm
Sunday : Closed

Keep In Touch

We are happy to answer your questions at desaieyehospital@hvdeh.org

Copyright 2017 PBMA's H. V. Desai Eye Hospital
Best viewed in IE 10+, Firefox 20+, Chrome , Safari5+, Opera12+
Online Appointment
Go to Top